Skip to main content
Premium Trial:

Request an Annual Quote

Agilent to Manufacture siRNA for Intradigm Rx

NEW YORK (GenomeWeb News) — Agilent Technologies will manufacture the small-interfering RNA component of an RNAi therapeutic being developed by Intradigm, the firms said last week.
 
Agilent will supply the siRNA material for use in Intradigm’s preclinical oncology candidate, ICS-283. According to the firms, ICS-283 is the only RNAi therapeutic in development against a clinically validated oncology target, in this case vascular endothelial growth factor.
 
Intradigm has developed the RNAi Nanoplex delivery system for administering RNAi therapeutics.
 
Financial terms of the alliance were not disclosed.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.